AR079903A1 - Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. - Google Patents
Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit.Info
- Publication number
- AR079903A1 AR079903A1 ARP110100123A ARP110100123A AR079903A1 AR 079903 A1 AR079903 A1 AR 079903A1 AR P110100123 A ARP110100123 A AR P110100123A AR P110100123 A ARP110100123 A AR P110100123A AR 079903 A1 AR079903 A1 AR 079903A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- antibody
- heavy chain
- light chain
- sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Reivindicacion 1: Una formulacion farmacéutica, que comprende una solucion acuosa de un buffer de ácido glutámico y un anticuerpo que comprende una CDR1 de cadena pesada que comprende SEQ ID N°:5, una CDR2 de cadena pesada que comprende SEQ ID N°:7, una CDR3 de cadena pesada que comprende SEQ ID N°:8, una CDR1 de cadena liviana que comprende SEQ ID N°:9, una CDR2 de cadena liviana que comprende SEQ ID N°:10, y una CDR3 de cadena liviana que comprende SEQ ID N°:11, en donde dicho anticuerpo, o fragmento del mismo, se une específicamente al receptor A de IL-17 humana, y en donde: a) dicho buffer de ácido glutámico comprende una concentracion de ácido glutámico de 5-30 mM +- 0,2 mM; b) dicho buffer de ácido glutámico comprende un pH de 4,5-5,2 +- 0,2; c) dicha formulacion además comprende 2-4% prolina (p/v) y 0,005-0,02% (p/v) polisorbato 20; y d) dicho anticuerpo se encuentra en una concentracion de 100 a 150 mg/ml. Reivindicacion 11: Uso de un anticuerpo, en donde dicho anticuerpo se selecciona del grupo que consta de: a) un anticuerpo que comprende una CDR1 de cadena pesada que comprende SEQ ID N°:5, una CDR2 de cadena pesada que comprende SEQ ID N°: 7, una CDR3 de cadena pesada que comprende SEQ ID N°:8, una CDR1 de cadena liviana que comprende SEQ ID N°:9, una CDR2 de cadena liviana que comprende SEQ ID N°:10, y una CDR3 de cadena liviana que comprende SEQ ID N°:11, en donde dicho anticuerpo, o fragmento del mismo, se une específicamente al receptor A de IL-17 humana; b) un anticuerpo que comprende una secuencia de dominio variable de cadena pesada que comprende SEQ ID N°:3 y una secuencia de dominio variable de cadena liviana que comprende SEQ ID N°:4, en donde dicho anticuerpo, o fragmento del mismo, se une específicamente al receptor A de IL-17 humana; y c) un anticuerpo que comprende una secuencia de cadena pesada que comprende SEQ ID N°:1 y una secuencia de cadena liviana que comprende SEQ ID N°:2, o en forma alternativa, una secuencia de cadena pesada que comprende SEQ ID N°:12 y una secuencia de cadena liviana que comprende SEQ ID N°:2, caracterizado porque es para la manufactura de un medicamento para tratar psoriasis en un paciente humano que lo necesite.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29538710P | 2010-01-15 | 2010-01-15 | |
US42205910P | 2010-12-10 | 2010-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR079903A1 true AR079903A1 (es) | 2012-02-29 |
Family
ID=43858045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110100123A AR079903A1 (es) | 2010-01-15 | 2011-01-14 | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. |
Country Status (37)
Country | Link |
---|---|
US (5) | US8883151B2 (es) |
EP (3) | EP3632466A1 (es) |
JP (2) | JP5743234B2 (es) |
KR (1) | KR101766936B1 (es) |
CN (1) | CN102821787B (es) |
AR (1) | AR079903A1 (es) |
AU (3) | AU2011205402B2 (es) |
BR (1) | BR112012017150B1 (es) |
CA (1) | CA2787128C (es) |
CL (1) | CL2012001966A1 (es) |
CO (1) | CO6640206A2 (es) |
CR (1) | CR20120419A (es) |
CY (2) | CY1119852T1 (es) |
DK (2) | DK2523688T3 (es) |
EA (2) | EA031209B9 (es) |
ES (2) | ES2753216T3 (es) |
HR (1) | HRP20171939T1 (es) |
HU (2) | HUE035618T2 (es) |
IL (1) | IL220602B (es) |
IN (1) | IN2012DN06720A (es) |
LT (2) | LT3295957T (es) |
MA (1) | MA33989B1 (es) |
MX (1) | MX349856B (es) |
MY (1) | MY182680A (es) |
NO (1) | NO2523688T3 (es) |
NZ (1) | NZ601125A (es) |
PE (1) | PE20121691A1 (es) |
PL (2) | PL3295957T3 (es) |
PT (2) | PT3295957T (es) |
RS (2) | RS56781B1 (es) |
SG (2) | SG10201604093XA (es) |
SI (2) | SI3295957T1 (es) |
TN (1) | TN2012000335A1 (es) |
TW (1) | TWI554282B (es) |
UA (1) | UA112288C2 (es) |
WO (1) | WO2011088120A1 (es) |
ZA (1) | ZA201205167B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
MY182680A (en) | 2010-01-15 | 2021-01-29 | Amgen K A Inc | Antibody formulation and therapeutic regimens |
ES2716088T3 (es) | 2010-02-04 | 2019-06-10 | Csl Behring Ag | Preparado de inmunoglobulina |
EP3546483A1 (en) | 2010-05-20 | 2019-10-02 | Ablynx N.V. | Biological materials related to her3 |
WO2012040518A2 (en) | 2010-09-22 | 2012-03-29 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
SG193963A1 (en) * | 2011-04-07 | 2013-11-29 | Glaxosmithkline Llc | Formulations with reduced viscosity |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
US20140234330A1 (en) * | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
US9914779B2 (en) | 2011-11-23 | 2018-03-13 | Amgen Inc. | Administration of alpha4beta7 hetero-dimer-specific antibody |
SI2822590T1 (sl) * | 2012-03-07 | 2017-01-31 | Eli Lilly And Company | Formulacije s protitelesi proti IL-17 |
AU2013262083A1 (en) | 2012-05-14 | 2014-11-06 | Novo Nordisk A/S | Stabilised protein solutions |
AU2014238148A1 (en) | 2013-03-15 | 2015-10-08 | Amgen Inc. | Methods for treating psoriasis using an anti-IL-23 antibody |
EA201591579A1 (ru) | 2013-03-15 | 2016-01-29 | Амген Инк. | Способы лечения болезни крона при помощи анти-il-23 антитела |
US20170174772A1 (en) * | 2014-03-31 | 2017-06-22 | Kirin-Amgen, Inc. | Methods of treating nail and scalp psoriasis |
EP3467501B1 (en) | 2014-05-16 | 2020-11-04 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
CA2962910C (en) * | 2014-08-26 | 2022-11-22 | Kirin-Amgen, Inc. | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy |
EP3193171B1 (en) * | 2014-09-10 | 2019-05-29 | NOF Corporation | Use of a protein adsorption inhibitor and method for inhibiting protein adsorption |
JP6909208B2 (ja) | 2015-09-17 | 2021-07-28 | アムジェン インコーポレイテッド | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 |
WO2017077391A2 (en) | 2015-11-04 | 2017-05-11 | Astrazeneca Ab | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
CN108472367A (zh) | 2015-12-22 | 2018-08-31 | 美国安进公司 | 作为对il23拮抗剂的临床应答的预测因子的ccl20 |
CN114265251A (zh) | 2016-04-19 | 2022-04-01 | Sage电致变色显示有限公司 | 包括透明导电氧化物层和汇流条的电致变色装置和其形成方法 |
GB201612043D0 (en) * | 2016-07-11 | 2016-08-24 | Crescendo Biologics Ltd | Composition for treatment of disorders |
CA2974531A1 (en) * | 2017-07-26 | 2019-01-26 | Michael Giroux | Safety anchor and roof vent |
GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
KR20210032441A (ko) | 2018-07-13 | 2021-03-24 | 아스트라제네카 콜라보레이션 벤처스, 엘엘씨 | 브라지쿠맙을 이용한 궤양성 대장염의 치료 |
MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
WO2021050563A1 (en) * | 2019-09-09 | 2021-03-18 | The Rockefeller University | Antibody treatment for lesional tissue of hidradenitis suppurativa |
JP2022547678A (ja) | 2019-09-11 | 2022-11-15 | ボシュ ヘルス アイルランド リミテッド | Il-17ra抗体を用いた非アルコール性脂肪性肝疾患(nafld)の治療方法 |
CN112891530B (zh) * | 2020-06-19 | 2021-08-24 | 北京东方百泰生物科技股份有限公司 | 一种抗il-17ra单克隆抗体的注射制剂 |
WO2022241148A1 (en) * | 2021-05-12 | 2022-11-17 | Anaptysbio, Inc. | Antibody composition |
WO2023240071A1 (en) * | 2022-06-06 | 2023-12-14 | Fusion Pharmaceuticals Inc. | Methods of dosing therapeutic agents |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1000835A (en) | 1911-06-19 | 1911-08-15 | Stewart A Minnick | Calipers. |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
IL98078A0 (en) | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
GB8807803D0 (en) | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
DE59010941D1 (de) | 1989-04-21 | 2005-03-24 | Amgen Inc | TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs |
DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
DK0398327T4 (da) | 1989-05-18 | 2013-04-15 | Yeda Res & Dev | Tumornekrosefaktor-bindende protein, dets oprensning og antistoffer dertil |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
US5703088A (en) | 1989-08-21 | 1997-12-30 | Beth Israel Deaconess Medical Center, Inc. | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
AU630497B2 (en) | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
DK0939121T4 (da) | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
JPH03127800A (ja) | 1989-10-13 | 1991-05-30 | Teijin Ltd | 腫瘍壊死因子活性抑制物質 |
AU642938B2 (en) | 1989-12-13 | 1993-11-04 | Yeda Research And Development Co. Ltd. | Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1) |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
GB2243569A (en) | 1990-05-02 | 1991-11-06 | Andrew Langdon | Brush with timer |
ATE169030T1 (de) | 1990-06-28 | 1998-08-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
WO1992001002A1 (fr) | 1990-07-11 | 1992-01-23 | Teijin Limited | Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation |
CA2100329C (en) | 1991-01-18 | 2009-09-29 | David F. Carmichael | Methods for treating tumor necrosis factor mediated diseases |
EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
WO1993007863A1 (en) | 1991-10-15 | 1993-04-29 | Mullarkey Michael F | Methods and compositions for treating allergic reactions |
US5716805A (en) | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
WO1993019777A1 (en) | 1992-03-30 | 1993-10-14 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
DK0639079T3 (da) | 1992-04-30 | 2000-06-13 | Amgen Inc | Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme |
JPH05312248A (ja) | 1992-05-08 | 1993-11-22 | Nissan Motor Co Ltd | シフトレバー装置 |
WO1994006476A1 (en) | 1992-09-15 | 1994-03-31 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
US6680057B1 (en) | 1995-03-23 | 2004-01-20 | Immunex Corporation | Methods of treating autoimmune disease by administering interleukin-17 receptor |
JP4373495B2 (ja) | 1995-03-23 | 2009-11-25 | イミュネックス・コーポレーション | Il−17受容体 |
US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
WO1997004097A2 (en) | 1995-07-19 | 1997-02-06 | Genetics Institute, Inc. | Human ctla-8 and uses of ctla-8-related proteins |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
US6406867B1 (en) | 1996-08-16 | 2002-06-18 | Human Genome Sciences, Inc. | Antibody to human endokine alpha and methods of use |
DE69739375D1 (de) | 1996-11-27 | 2009-06-04 | Immunex Corp | Verfahren zur regulierung der stickstoffmonoxid-erzeugung |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6635443B1 (en) | 1997-09-17 | 2003-10-21 | Human Genome Sciences, Inc. | Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein |
US6482923B1 (en) | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
JP3577586B2 (ja) | 1998-05-15 | 2004-10-13 | ジェネンテック・インコーポレーテッド | Il−17相同的ポリペプチドとその治療用途 |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
HUP0203133A3 (en) | 1999-10-04 | 2005-07-28 | Chiron Corp Emeryville | Stabilized liquid polypeptide-containing pharmaceutical compositions |
AR030554A1 (es) | 2000-03-16 | 2003-08-27 | Amgen Inc | Moleculas similares a receptores il-17 y usos de las mismas |
AR028256A1 (es) | 2000-03-16 | 2003-04-30 | Amgen Inc | Moleculas similares a receptores il-17 y usos de las mismas |
US20030180255A1 (en) | 2000-08-24 | 2003-09-25 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
EP1326626B1 (en) | 2000-10-18 | 2020-04-01 | Immunex Corporation | Methods for treating rheumatoid arthritis using il-17 antagonists |
WO2004003019A2 (en) | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
WO2003072060A2 (en) | 2002-02-27 | 2003-09-04 | Immunex Corporation | Polypeptide formulation |
WO2004002519A1 (en) | 2002-06-27 | 2004-01-08 | Smithkline Beecham Corporation | Methods of treating or preventing ibd with il-18 |
DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
US20050070460A1 (en) | 2003-08-05 | 2005-03-31 | 3M Innovative Properties Company | Infection prophylaxis using immune response modifier compounds |
GB0321703D0 (en) * | 2003-09-16 | 2003-10-15 | Imerys Minerals Ltd | Surface modified fillers for polymer resin compositions |
ES2553987T3 (es) | 2003-12-25 | 2015-12-15 | Kyowa Hakko Kirin Co., Ltd. | Preparación farmacéutica de base acuosa estable que contiene anticuerpo |
IL159670A0 (en) | 2003-12-31 | 2004-06-01 | Yeda Res & Dev | Use of il-18 binding protein in inflammations |
WO2005121190A2 (en) | 2004-06-04 | 2005-12-22 | Designer Molecules Inc. | Free-radical curable polyesters and methods for use thereof |
GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
BRPI0608210A2 (pt) | 2005-02-14 | 2010-11-09 | Wyeth Corp | métodos de diagnóstico de um distúrbio relacionado com il-17f em um indivìduo e de seleção de compostos capazes de inibirem a ligação de il-17f em il-17r, uso de um antagonista de il-17f, composição farmacêutica, e, adjuvante de vacina |
EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS |
CA2615122A1 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
AU2006295340B2 (en) | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
JP2009507023A (ja) | 2005-09-01 | 2009-02-19 | シェーリング コーポレイション | 自己免疫性眼炎症性疾患を処置するためのil−23およびil−17のアンタゴニストの使用 |
WO2007047738A1 (en) | 2005-10-18 | 2007-04-26 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
EP1942868B2 (en) | 2005-11-01 | 2023-10-04 | Wyeth LLC | Sodium chloride solution for drug reconstitution or dilution |
EP1977763A4 (en) * | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
CA2638811A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
CN101541833B (zh) * | 2006-10-02 | 2014-01-29 | 麒麟-安姆根有限公司 | Il-17受体a抗原结合蛋白质 |
WO2008049070A2 (en) | 2006-10-18 | 2008-04-24 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
JP5577098B2 (ja) * | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
FR2910324B1 (fr) | 2006-12-21 | 2009-03-06 | Biomerieux Sa | Nouveau medicament pour le traitement d'un cancer gastrique |
GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
CN101679497A (zh) | 2007-03-26 | 2010-03-24 | 津莫吉尼蒂克斯公司 | 可溶性il-17ra/rc融合蛋白以及相关方法 |
EP2170958A1 (en) | 2007-06-13 | 2010-04-07 | Amgen Inc. | Il-17 heteromeric receptor complex |
US20110014676A1 (en) | 2007-06-29 | 2011-01-20 | Battelle Memorial Institute | Protein stabilization |
EP2190476A1 (en) | 2007-08-17 | 2010-06-02 | Amgen, Inc | Formulations of antibodies and fc-fusion molecules using polycations |
BRPI0907196B1 (pt) | 2008-02-21 | 2021-05-25 | Kirin-Amgen Inc | Uso de um antagonista de il-17ra-il-17rb |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
MY182680A (en) | 2010-01-15 | 2021-01-29 | Amgen K A Inc | Antibody formulation and therapeutic regimens |
EP4137514A1 (en) | 2010-10-08 | 2023-02-22 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
AR083546A1 (es) | 2010-10-25 | 2013-03-06 | Genentech Inc | Tratamiento de inflamacion gastrointestinal, soriasis y asma |
US20140044727A1 (en) * | 2011-04-07 | 2014-02-13 | Glaxosmithkline Llc | Formulations with reduced viscosity |
SG193963A1 (en) * | 2011-04-07 | 2013-11-29 | Glaxosmithkline Llc | Formulations with reduced viscosity |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
US20170174772A1 (en) | 2014-03-31 | 2017-06-22 | Kirin-Amgen, Inc. | Methods of treating nail and scalp psoriasis |
CA2962910C (en) | 2014-08-26 | 2022-11-22 | Kirin-Amgen, Inc. | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy |
-
2011
- 2011-01-12 MY MYPI2016001562A patent/MY182680A/en unknown
- 2011-01-12 DK DK11705713.3T patent/DK2523688T3/en active
- 2011-01-12 CA CA2787128A patent/CA2787128C/en active Active
- 2011-01-12 SI SI201131792T patent/SI3295957T1/sl unknown
- 2011-01-12 DK DK17195530.5T patent/DK3295957T3/da active
- 2011-01-12 EA EA201290653A patent/EA031209B9/ru not_active IP Right Cessation
- 2011-01-12 NO NO11705713A patent/NO2523688T3/no unknown
- 2011-01-12 SI SI201131350T patent/SI2523688T1/en unknown
- 2011-01-12 CN CN201180012846.1A patent/CN102821787B/zh active Active
- 2011-01-12 RS RS20171311A patent/RS56781B1/sr unknown
- 2011-01-12 SG SG10201604093XA patent/SG10201604093XA/en unknown
- 2011-01-12 SG SG2012051108A patent/SG182468A1/en unknown
- 2011-01-12 EA EA201891433A patent/EA201891433A3/ru unknown
- 2011-01-12 EP EP19189613.3A patent/EP3632466A1/en not_active Withdrawn
- 2011-01-12 PT PT171955305T patent/PT3295957T/pt unknown
- 2011-01-12 KR KR1020127021299A patent/KR101766936B1/ko active IP Right Grant
- 2011-01-12 ES ES17195530T patent/ES2753216T3/es active Active
- 2011-01-12 PE PE2012001003A patent/PE20121691A1/es active IP Right Grant
- 2011-01-12 EP EP17195530.5A patent/EP3295957B1/en active Active
- 2011-01-12 HU HUE11705713A patent/HUE035618T2/en unknown
- 2011-01-12 IN IN6720DEN2012 patent/IN2012DN06720A/en unknown
- 2011-01-12 PL PL17195530T patent/PL3295957T3/pl unknown
- 2011-01-12 UA UAA201209849A patent/UA112288C2/uk unknown
- 2011-01-12 PT PT117057133T patent/PT2523688T/pt unknown
- 2011-01-12 PL PL11705713T patent/PL2523688T3/pl unknown
- 2011-01-12 EP EP11705713.3A patent/EP2523688B1/en active Active
- 2011-01-12 LT LTEP17195530.5T patent/LT3295957T/lt unknown
- 2011-01-12 AU AU2011205402A patent/AU2011205402B2/en active Active
- 2011-01-12 RS RS20191335A patent/RS59743B1/sr unknown
- 2011-01-12 MA MA35124A patent/MA33989B1/fr unknown
- 2011-01-12 MX MX2012008213A patent/MX349856B/es active IP Right Grant
- 2011-01-12 WO PCT/US2011/020985 patent/WO2011088120A1/en active Application Filing
- 2011-01-12 BR BR112012017150-0A patent/BR112012017150B1/pt active IP Right Grant
- 2011-01-12 US US13/521,999 patent/US8883151B2/en active Active
- 2011-01-12 ES ES11705713.3T patent/ES2652637T3/es active Active
- 2011-01-12 NZ NZ601125A patent/NZ601125A/en unknown
- 2011-01-12 HU HUE17195530A patent/HUE046670T2/hu unknown
- 2011-01-12 LT LTEP11705713.3T patent/LT2523688T/lt unknown
- 2011-01-12 JP JP2012549047A patent/JP5743234B2/ja active Active
- 2011-01-14 AR ARP110100123A patent/AR079903A1/es not_active Application Discontinuation
- 2011-01-14 TW TW100101536A patent/TWI554282B/zh active
-
2012
- 2012-06-24 IL IL220602A patent/IL220602B/en active IP Right Grant
- 2012-06-26 TN TNP2012000335A patent/TN2012000335A1/en unknown
- 2012-07-11 ZA ZA2012/05167A patent/ZA201205167B/en unknown
- 2012-07-13 CL CL2012001966A patent/CL2012001966A1/es unknown
- 2012-08-10 CO CO12135074A patent/CO6640206A2/es unknown
- 2012-08-10 CR CR20120419A patent/CR20120419A/es unknown
-
2014
- 2014-09-29 US US14/499,691 patent/US10072085B2/en active Active
- 2014-12-05 JP JP2014247218A patent/JP2015052017A/ja active Pending
-
2015
- 2015-04-21 AU AU2015202023A patent/AU2015202023B2/en active Active
-
2017
- 2017-08-18 AU AU2017216579A patent/AU2017216579A1/en not_active Abandoned
- 2017-12-14 HR HRP20171939TT patent/HRP20171939T1/hr unknown
-
2018
- 2018-01-09 CY CY20181100022T patent/CY1119852T1/el unknown
- 2018-08-02 US US16/053,564 patent/US10808033B2/en active Active
-
2019
- 2019-11-04 CY CY20191101143T patent/CY1122466T1/el unknown
-
2020
- 2020-09-08 US US17/015,029 patent/US11505612B2/en active Active
-
2022
- 2022-10-11 US US18/045,534 patent/US20230192873A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR079903A1 (es) | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. | |
CL2020001579A1 (es) | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. (divisional solicitud 201303145) | |
CY1123657T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
AR059922A1 (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos | |
AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
PE20142243A1 (es) | Anticuerpos que se unen a ox40 y sus usos | |
AR076195A1 (es) | Anticuerpos biespecificos anti-erbb-1/anti-c-met | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
RU2011144312A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИ-ErbB-3/АНТИ-С-МЕТ АНТИТЕЛА | |
ES2564281T3 (es) | Formulación de anticuerpos Abeta | |
UA113728C2 (xx) | Фармацевтична композиція, яка містить антитіло до pcsk9 людини | |
PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
ECSP13012792A (es) | Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9 | |
CO6382125A2 (es) | Inhibidores de proteína quinasa | |
PA8635501A1 (es) | Uso de un anticuerpo para el tratamiento del lupus | |
AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
CL2011000230A1 (es) | Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado. | |
NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
PE20170687A1 (es) | Proteinas de enlace a cd127 | |
PE20141706A1 (es) | Anticuerpos de union a trombina y usos del mismo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |